{"id":745364,"date":"2016-06-09T16:07:00","date_gmt":"2016-06-09T16:07:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/"},"modified":"2025-11-07T01:25:47","modified_gmt":"2025-11-07T06:25:47","slug":"merck-to-acquire-afferent-pharmaceuticals","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/","title":{"rendered":"Merck to Acquire Afferent Pharmaceuticals"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Afferent Pharmaceuticals announced today that the two companies have<br \/>\n      signed a definitive agreement under which Merck will acquire this<br \/>\n      privately held pharmaceutical company. Afferent Pharmaceuticals is a<br \/>\n      leader in the development of therapeutic candidates targeting the P2X3<br \/>\n      receptor for the treatment of common, poorly-managed, neurogenic<br \/>\n      conditions. Afferent\u2019s lead investigational candidate, AF-219, is a<br \/>\n      selective, non-narcotic, orally-administered P2X3 antagonist currently<br \/>\n      being evaluated in a Phase 2b clinical trial for the treatment of<br \/>\n      refractory, chronic cough as well as in a Phase 2 clinical trial in<br \/>\n      idiopathic pulmonary fibrosis (IPF) with cough.\n    <\/p>\n<p>\n      \u201cAfferent has pioneered the clinical development of novel<br \/>\n      investigational candidates selectively targeting the P2X3 receptor, an<br \/>\n      exciting area of research,\u201d said Dr. Roger M. Perlmutter, president,<br \/>\n      Merck Research Laboratories. \u201cWe look forward to advancing these<br \/>\n      innovative molecules for patients with conditions like chronic cough, an<br \/>\n      area of significant unmet medical need.\u201d\n    <\/p>\n<p>\n      Under terms of the agreement, Merck, through a subsidiary, will acquire<br \/>\n      all outstanding stock of Afferent in exchange for an upfront payment of<br \/>\n      $500 million in cash. Also, Afferent shareholders will be eligible to<br \/>\n      receive a total of up to an additional $750 million associated with the<br \/>\n      attainment of certain clinical development and commercial milestones for<br \/>\n      multiple indications and candidates, including AF-219.\n    <\/p>\n<p>\n      \u201cThis achievement is a reflection of the talent and hard work of the<br \/>\n      experienced Afferent team in advancing the science of P2X3 receptors and<br \/>\n      the clinical development of our novel therapeutic candidates,\u201d said<br \/>\n      Kathleen Sereda Glaub, chief executive officer, Afferent<br \/>\n      Pharmaceuticals. \u201cWe are very pleased to enter into this agreement given<br \/>\n      Merck\u2019s reputation for maximizing opportunities around novel mechanisms.<br \/>\n      This agreement with Merck creates significant value for Afferent<br \/>\n      shareholders while enhancing the potential of our portfolio to provide<br \/>\n      meaningful benefits to patients globally.\u201d\n    <\/p>\n<p>\n      Data on cough frequency from the first cohort of a Phase 2b<br \/>\n      dose-escalation clinical trial of AF-219 in patients with chronic cough<br \/>\n      were presented at the 2016 American Thoracic Society (ATS) International<br \/>\n      Conference. The results of the second cohort, which is examining lower<br \/>\n      doses, are expected to be presented at a future scientific congress.\n    <\/p>\n<p>\n      The closing of the transaction will be subject to certain conditions,<br \/>\n      including the expiration of the waiting period under the<br \/>\n      Hart-Scott-Rodino Antitrust Improvements Act and other customary<br \/>\n      conditions. The companies anticipate the transaction will close in the<br \/>\n      third quarter of 2016.\n    <\/p>\n<p>\n      <b>About P2X3 Receptor-Mediated Sensitization<\/b>\n    <\/p>\n<p>\n      Afferent\u2019s clinical candidates, AF-219 and AF-130, are orally available<br \/>\n      investigational candidates that selectively block P2X3 receptors. P2X3<br \/>\n      receptors are believed to play a key role in the sensitization of<br \/>\n      certain sensory nerves, notably C-fiber afferents. These nerves become<br \/>\n      activated and sensitized under pathological conditions mediated by a<br \/>\n      common cellular signal, ATP, when it is released in high concentrations<br \/>\n      due to cellular distress following injury or infection. Afferent\u2019s<br \/>\n      compounds are designed to selectively block ATP activation of P2X3<br \/>\n      channels, potentially reducing a range of sensory signs and symptoms.\n    <\/p>\n<p>\n      <b>About Chronic Cough<\/b>\n    <\/p>\n<p>\n      The prevalence of chronic cough (a cough lasting more than 8 weeks) is<br \/>\n      estimated to be approximately 10 percent of adults in the U.S. While an<br \/>\n      underlying condition may contribute to cough in many of these patients,<br \/>\n      in 20-40 percent of cases no underlying condition can be identified and<br \/>\n      hence these patients are typically not responsive to symptomatic<br \/>\n      treatment. Additionally, many treatment-responsive patients are not<br \/>\n      well-controlled for their cough. There are currently no approved<br \/>\n      therapies for the treatment of chronic cough.\n    <\/p>\n<p>\n      <b>About Afferent Pharmaceuticals<\/b>\n    <\/p>\n<p>\n      Afferent Pharmaceuticals is a clinical-stage biotechnology company and a<br \/>\n      leader in the development of novel drugs for the treatment of a range of<br \/>\n      neurogenic conditions. These conditions affect millions of patients who<br \/>\n      suffer from chronic respiratory and urologic sensory pathologies, as<br \/>\n      well as chronic pain and cardiovascular disorders, and who have limited,<br \/>\n      if any, treatment options. These chronic pathologies arise when certain<br \/>\n      nerves become hyper-sensitized as a result of inflammation, distress,<br \/>\n      infection or tissue injury, which may remain chronically sensitized for<br \/>\n      months and even years.\n    <\/p>\n<p>\n      Afferent was founded by Anthony Ford, Ph.D., Pappas Ventures, Third Rock<br \/>\n      Ventures, Domain Associates, New Leaf Venture Partners and Roche<br \/>\n      Ventures, following the exclusive license of Roche\u2019s P2X3 program to<br \/>\n      Afferent. The lead molecule, AF-219, is in Phase 2 clinical development<br \/>\n      for the treatment of chronic cough, and idiopathic pulmonary fibrosis<br \/>\n      (IPF) with cough. A second compound, AF-130, completed Phase 1 clinical<br \/>\n      testing and is scheduled to advance to Phase 2 trials in non-respiratory<br \/>\n      conditions.\n    <\/p>\n<p>\n      For more information on the company, please visit Afferent\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.afferentpharma.com&amp;esheet=51358904&amp;newsitemid=20160609006459&amp;lan=en-US&amp;anchor=www.afferentpharma.com&amp;index=1&amp;md5=679b4a814de68a506eff1f766db7c76a\" rel=\"nofollow\">www.afferentpharma.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51358904&amp;newsitemid=20160609006459&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=9bc6968cdc08ccfb08e9f5202b7fb034\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51358904&amp;newsitemid=20160609006459&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=25e16ab18fc4d38ab84774933a2f359d\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51358904&amp;newsitemid=20160609006459&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=8b98a635f33d24051febe593b9ab51a0\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51358904&amp;newsitemid=20160609006459&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=2fd5aba4b49b327ca1eeefd828ea9d80\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51358904&amp;newsitemid=20160609006459&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=b48b3ffdd91b436a207917f7a92bcfaa\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51358904&amp;newsitemid=20160609006459&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=d75ba27cd742a32bf4ea63f6e53e2c81\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160609006459r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Michael\u00a0Close,        267-305-1211<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Justin        Holko, 908-740-1879<br \/>or<br \/>Afferent<br \/>Media:<br \/>Susan        Kinkead, 415-509-3610<br \/>or<br \/>Investors:<br \/>Dulce Dizon,        650-286-1276     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions. Afferent\u2019s lead investigational candidate, AF-219, is a selective, non-narcotic, orally-administered P2X3 antagonist currently being evaluated in a Phase 2b clinical trial for the treatment of refractory, chronic cough as well as in a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF) with cough. \u201cAfferent has pioneered the clinical development of novel investigational candidates selectively targeting the P2X3 receptor, an exciting area of research,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cWe look forward to advancing these<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,64,289],"class_list":["post-745364","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Acquire Afferent Pharmaceuticals - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Acquire Afferent Pharmaceuticals - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions. Afferent\u2019s lead investigational candidate, AF-219, is a selective, non-narcotic, orally-administered P2X3 antagonist currently being evaluated in a Phase 2b clinical trial for the treatment of refractory, chronic cough as well as in a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF) with cough. \u201cAfferent has pioneered the clinical development of novel investigational candidates selectively targeting the P2X3 receptor, an exciting area of research,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cWe look forward to advancing these\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-afferent-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-afferent-pharmaceuticals\\\/\",\"name\":\"Merck to Acquire Afferent Pharmaceuticals - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-06-09T16:07:00+00:00\",\"dateModified\":\"2025-11-07T06:25:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-afferent-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-afferent-pharmaceuticals\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-afferent-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Acquire Afferent Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Acquire Afferent Pharmaceuticals - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Acquire Afferent Pharmaceuticals - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions. Afferent\u2019s lead investigational candidate, AF-219, is a selective, non-narcotic, orally-administered P2X3 antagonist currently being evaluated in a Phase 2b clinical trial for the treatment of refractory, chronic cough as well as in a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF) with cough. \u201cAfferent has pioneered the clinical development of novel investigational candidates selectively targeting the P2X3 receptor, an exciting area of research,\u201d said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cWe look forward to advancing these","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:47+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/","name":"Merck to Acquire Afferent Pharmaceuticals - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-06-09T16:07:00+00:00","dateModified":"2025-11-07T06:25:47+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-afferent-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Acquire Afferent Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"53bb0569-0478-4d63-9de3-72731aa1f67c","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2016\/06\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2016\/06\/1\/Afferent-Logo.jpg","size":"33156","File Upload":""}],"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745364\/revisions"}],"predecessor-version":[{"id":3674763,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745364\/revisions\/3674763"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745364"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}